Novartis AG (NYSE:NVS) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. trimmed its position in shares of Novartis AG (NYSE:NVSFree Report) by 44.3% during the first quarter, Holdings Channel reports. The firm owned 58,465 shares of the company’s stock after selling 46,462 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Novartis were worth $6,518,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NVS. JPMorgan Chase & Co. boosted its position in shares of Novartis by 35.6% in the 4th quarter. JPMorgan Chase & Co. now owns 423,142 shares of the company’s stock worth $41,176,000 after buying an additional 111,066 shares in the last quarter. Altrius Capital Management Inc lifted its holdings in shares of Novartis by 4.5% in the fourth quarter. Altrius Capital Management Inc now owns 77,783 shares of the company’s stock valued at $7,569,000 after purchasing an additional 3,345 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Novartis in the fourth quarter valued at about $225,000. Charles Schwab Investment Management Inc. grew its position in shares of Novartis by 5.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 165,442 shares of the company’s stock valued at $16,099,000 after purchasing an additional 8,186 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new position in shares of Novartis during the 4th quarter worth approximately $9,365,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Up 2.0%

Shares of NYSE NVS opened at $120.36 on Friday. The firm has a market cap of $254.24 billion, a P/E ratio of 18.81, a price-to-earnings-growth ratio of 1.70 and a beta of 0.59. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.61 and a current ratio of 0.79. Novartis AG has a 1 year low of $96.06 and a 1 year high of $120.92. The firm’s 50 day moving average price is $113.76 and its 200 day moving average price is $107.94.

Novartis (NYSE:NVSGet Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.16. Novartis had a return on equity of 39.44% and a net margin of 24.70%. The business had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. During the same quarter in the previous year, the business earned $1.80 earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, BNP Paribas upgraded Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and a consensus target price of $123.38.

Check Out Our Latest Report on NVS

Novartis Profile

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Read More

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVSFree Report).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.